-
Harper DM, Verdenius I, Harris GD, Barnett AL, Rosemergey B, Arey AM, Wall J, Malnar GJ. The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series. Preventive Medicine. 2014 61: 20–25.
-
Harper DM, Irons BB, Alexander NM, Comes JC, Smith MS, et al. (2014) Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention. PLoS ONE 2014 Feb 14:9(2): e88493. doi:10.1371/journal.pone.0088493
-
Harper DM, Groner JA. Positive High-Risk HPV Test with Negative Cytology--A Conundrum and Blessing of Our Latest Technology. Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):10-1.
-
Groner JA, Harris GD, Harper DM. Reduction in HPV prevalence--no evidence to support HPV vaccination reduces HPV prevalence. Journal of Infectious Diseases. 2014 Apr 15;209(8):1302-4.
-
Harper DM. Conclusions about HPV4 efficacy based on alternate dosing schedules and less than three dose immunogenicity is inappropriate Journal of Infectious Diseases 2014; Feb 5. doi: 10.1093/infdis/jiu072
-
Sandri KJ, Verdenius I, Bartley MJ, Else BM, Paynter CA, Rosemergey BE, Harris GD, Malnar GJ, Harper SM, Griffith RS, Bonham AJ, Harper DM. Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates. PLoS One. 2014 May 9;9(5):e96277.
-
Else BM, Bartley MJ, Arey AM, Barnett AL, Rosemergey B, Paynter CA, Verdenius I, Harris GD, Harper SM, Groner AJ, Malnar GJ, Wall J, Bonham AJ, Harper DM. In a Safety Net Population HPV4 Vaccine Adherence Worsens as BMI Increases. PLoS ONE. 2014 Jul 30;9(7): e103172. doi:10.1371/journal.pone.0103172
-
Harper DM, Alexander NM, Ahern DA, Comes JC, Smith MS, Heutinck MA, Handley SM. Women have a preference for their male partner to be HPV vaccinated. PLoS One. 2014 May 14;9(5):e97119.
-
Alexander NM, Harper DM, Comes JC, Smith MS, Heutinck MA, Handley SM, Ahern DA. Intent to continue cervical cancer screening after HPV vaccination. PLoS One. 2014 Jun 10;9(6):e98665.
-
Harper DM, Demars LR. Primary Strategies for HPV Infection and Cervical Cancer Prevention. Clin Obstet Gynecol. 2014 Jun;57(2):256-278.
-
Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmeron J, Lehtinen M, Del Rosario-Raymundo M, Paavonen J, Teixeira J, Germar M, Peters K, Skinner R, Limson G, Castellsagué X, Poppe W, Ramjattan B, Klein T, Schwarz T, Chatterjee A, Tjalma W, Diaz-Mitoma F, Lewis D, Harper DM, Molijn A, van Doorn L, David MP, and Dubin G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against incident and persistent infection with non-vaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA: post hoc analysis from the PATRICIA randomized trial. Clinical and Vaccine Immunology. 2015 22(2):235-244.
-
Harper DM, Wall J, Verdenius I. Response to Philanthropic support of HPV vaccination efforts. Prev Med. 2015 Feb 2. pii: S0091-7435(15)00034-1. doi: 10.1016/j.ypmed.2014.12.042.
-
Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; Harper DM HPV PATRICIA Study Group. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.
-
Skinner SR, Apter D, Harper DM, De Carvalho N, , Konno R, Paavonen J, Romanowski B, Roteli-Martins C, Kandeil W, Mihalyi A, Struyf F. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases: a review of vaccine efficacy. Expert Review of Vaccines. 2015
-
Kreimer AR, Struyf F, Del Rosario Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM, Harper DM for the Costa Rica Vaccine Trial and the PATRICIA study groups. Efficacy of Fewer than Three Doses of a HPV-16/18 AS04 adjuvanted Vaccine: a Meta Analysis of Data from the Costa Rica Vaccine Trial and the PATRICIA Trial. Lancet Oncology. 2015. Lancet Oncol. 2015 Jun 9. pii: S1470-2045(15)00047-9. doi: 10.1016/S1470-2045(15)00047-9
-
Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Da Silva DP, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L,for the VIVIANE study group. Progression of HPV infection to cervical lesion or clearance in adult women: analysis of the control arm of the VIVIANE study. International Journal of Cancer. 2015
-
Hempstead LA and Harper DM. Incorporating Osteopathic Curriculum Into a Dually Accredited Residency Program: Maintaining Osteopathic Identity Under Single Graduate Medical Education Accreditation. Family Medicine 2015
-
Fernandez LM, Girdler RV, Wright RB, Harper DM. IIV3 reduced flu in HIV- pregnant women and infants, and in HIV+ pregnant women but not their infants. Ann Intern Med. 2015 Feb 17;162(4):JC6. doi: 10.7326/ACPJC-2015-162-4-006.
-
Fernandez LM, Harper DM. Screening for CIN 3 and Cervical Cancer: Primary HPV Testing: La detección de NIC 3 y el cáncer del cuello uterino: pruebas primarias VPH. Archivos Médicos de Atualización en Tracto Genital Inferior, Año VI, No. 12 Abril 2015 Section 3 pp 1-10.
-
Pendleton E, Ruffin MT, Harper DM. No evidence in US of HPV16/18 cancer precursor reduction. Vaccine. 2015